{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:37:45Z","timestamp":1784245065802,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015077","name":"Jagiellonian University Medical College Faculty of Medicine","doi-asserted-by":"publisher","award":["K\/ZDS\/002936"],"award-info":[{"award-number":["K\/ZDS\/002936"]}],"id":[{"id":"10.13039\/100015077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vph.2023.107153","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T21:27:31Z","timestamp":1676064451000},"page":"107153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effect of high-dose statin therapy on coagulation factors: Lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease"],"prefix":"10.1016","volume":"149","author":[{"given":"Konrad","family":"St\u0119pie\u0144","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Siudut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Konieczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2023.107153_bb0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1538-7836.2007.02799.x","article-title":"Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition","volume":"6","author":"Brummel-Ziedins","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2023.107153_bb0010","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/ATVBAHA.108.177402","article-title":"Tissue factor in coagulation: which? Where? When?","volume":"29","author":"Butenas","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107153_bb0015","article-title":"Fibrin clot properties in coronary artery disease: new determinants and prognostic markers","volume":"131","author":"Larsen","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/cvr\/cvp066","article-title":"Is thrombin a key player in the \u201ccoagulation-atherogenesis\u201d maze?","volume":"82","author":"Borissoff","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"2020","key":"10.1016\/j.vph.2023.107153_bb0025","first-page":"407","article-title":"ESC guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur. Heart J."},{"issue":"2016","key":"10.1016\/j.vph.2023.107153_bb0030","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2019","key":"10.1016\/j.vph.2023.107153_bb0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis."},{"issue":"2019","key":"10.1016\/j.vph.2023.107153_bb0040","first-page":"e285","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2023.107153_bb0045","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/ph15080919","article-title":"Statin use in Cancer patients with acute myocardial infarction and its impact on long-term mortality","volume":"15","author":"Stepien","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.vph.2023.107153_bb0050","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107153_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"Undas","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.vph.2023.107153_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0037-1613151","article-title":"Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study","volume":"88","author":"Cortellaro","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2023.107153_bb0065","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.16208","article-title":"Statins in prevention of thromboembolic events: from seminal studies to recent advances","volume":"132","author":"Undas","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1538-7836.2006.01882.x","article-title":"Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease","volume":"4","author":"Undas","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2023.107153_bb0075","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/eurheartj\/ehy014","article-title":"Rosuvastatin use improves measures of coagulation in patients with venous thrombosis","volume":"39","author":"Biedermann","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2023.107153_bb0080","unstructured":"Pleiotropic influence of rosuvastatin on apolipoproteins and their association with coagulation factor levels: results from the START trial - ISTH Congress Abstracts, (n.d.). https:\/\/abstracts.isth.org\/abstract\/pleiotropic-influence-of-rosuvastatin-on-apolipoproteins-and-their-association-with-coagulation-factor-levels-results-from-the-start-trial\/ (accessed October 20, 2022)."},{"key":"10.1016\/j.vph.2023.107153_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-021-00299-2","article-title":"Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study","volume":"19","author":"Bordbar","year":"2021","journal-title":"Thromb. J."},{"key":"10.1016\/j.vph.2023.107153_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.106977","article-title":"Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: association with lipoproteins and C-reactive protein","volume":"144","author":"Siudut","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2023.107153_bb0095","first-page":"942","article-title":"Worse long-term prognosis in myocardial infarction occurring at weekends or public holidays with insight into myocardial infarction with nonobstructive coronary arteries","volume":"130","author":"St\u0119pie\u0144","year":"2020","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.785246","article-title":"Clinical characteristics and long-term outcomes of MINOCA accompanied by active cancer: a retrospective insight into a cardio-oncology center registry","volume":"9","author":"Stepien","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0105","doi-asserted-by":"crossref","first-page":"850","DOI":"10.33963\/KP.15529","article-title":"Statins plus ezetimibe in the era of proprotein convertase subtilisin\/kexin type 9 inhibitors","volume":"78","author":"de Luca","year":"2020","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.vph.2023.107153_bb0110","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2009-05-222380","article-title":"Altered fibrin clot structure\/function in patients with idiopathic venous thromboembolism and in their relatives","volume":"114","author":"Undas","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.vph.2023.107153_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9072018","article-title":"Delayed thrombin generation is associated with minor bleedings in venous thromboembolism patients on rivaroxaban: usefulness of calibrated automated Thrombography","volume":"9","author":"Zalewski","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0120","first-page":"520","article-title":"Increase in the prevalence of metabolic syndrome in Poland: comparison of the results of the WOBASZ (2003\u20132005) and WOBASZ II (2013\u20132014) studies","volume":"131","author":"Rajca","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0125","article-title":"Secondary prevention of coronary heart disease in Poland: does sex matter? Results from the POLASPIRE survey","volume":"132","author":"Setny","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00001721-200112000-00015","article-title":"Lifestyle factors and coagulation activation markers: the Caerphilly study","volume":"12","author":"Yarnell","year":"2001","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.vph.2023.107153_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3343\/alm.2015.35.1.15","article-title":"Influence of blood lipids on global coagulation test results","volume":"35","author":"Kim","year":"2015","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.vph.2023.107153_bb0140","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/jth.15236","article-title":"Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"19","author":"Ngo","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2023.107153_bb0145","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.vph.2023.107153_bb0150","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2022.02.009","article-title":"Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients","volume":"346","author":"Paszek","year":"2022","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.vph.2023.107153_bb0155","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/jth.12531","article-title":"Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women","volume":"12","author":"Siegerink","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.vph.2023.107153_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-13174-5","article-title":"Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis","volume":"12","author":"Pallares Robles","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vph.2023.107153_bb0165","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/01.CIR.0000012146.07240.FD","article-title":"Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene","volume":"105","author":"Morishita","year":"2002","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2023.107153_bb0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.vph.2023.107153_bb0175","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vph.2023.107153_bb0180","article-title":"Impact of deficiency of intrinsic coagulation factors XI and XII on ex vivo Thrombus formation and clot lysis","volume":"3","author":"Govers-Riemslag","year":"2019","journal-title":"TH Open."},{"key":"10.1016\/j.vph.2023.107153_bb0185","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jth.13342","article-title":"Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway","volume":"14","author":"Colucci","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2023.107153_bb0190","article-title":"Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism","volume":"133\u2013134","author":"Z\u0105bczyk","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2023.107153_bb0195","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MBC.0b013e328346c2bb","article-title":"Activated factor XI and tissue factor in aortic stenosis: links with thrombin generation","volume":"22","author":"Luszczak","year":"2011","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.vph.2023.107153_bb0200","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"PACIFIC AMI investigators, a multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the Oral factor XIa inhibitor Asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.vph.2023.107153_bb0205","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"de Caterina","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2023.107153_bb0210","doi-asserted-by":"crossref","first-page":"741","DOI":"10.33963\/KP.a2022.0117","article-title":"Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances","volume":"80","author":"Atar","year":"2022","journal-title":"Kardiol. Pol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:22:01Z","timestamp":1761528121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189123000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":42,"alternative-id":["S1537189123000137"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107153","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of high-dose statin therapy on coagulation factors: Lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107153"}}